Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Summary

Primary Objective of Part 1 (Dose Escalation Phase): Evaluate the safety and tolerability of SKL27969, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of SKL27969 Primary Objective of Part 2 (Dose Expansion Phase): Evaluate the preliminary anti-tumor activity of SKL27969

Timeline

Start

2022-09-12

Primary completion

2024-03-01

Completion

2024-03-01

Outcome

Outcome not reported

Stopped (Business): “The study has been terminated based on portfolio prioritization. No safety trends or issues were identified at any dose level.”

Drugs

Indications